SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 29th, 2016 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of July 29, 2016, between Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
Exhibit 10.14 SHARE PURCHASE AGREEMENT THIS SHARE PURCHASE AGREEMENT ("Agreement") is dated as of November 27, 2001 and is entered into by and among Cellegy Pharmaceuticals, Inc., a California corporation ("Cellegy"), Vaxis Therapeutics Corporation, a...Share Purchase Agreement • March 12th, 2002 • Cellegy Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
AGREEMENTAsset Purchase Agreement • January 14th, 1998 • Cellegy Pharmaceuticals Inc • Pharmaceutical preparations • California
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 6th, 2022 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is made and entered into as of July 5, 2022, between Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”), and purchaser signatory hereto (the “Purchaser”).
RECITALSIndemnification Agreement • April 6th, 2004 • Cellegy Pharmaceuticals Inc • Pharmaceutical preparations • California
COMMON STOCK PURCHASE WARRANT ADAMIS PHARMACEUTICALS CORPORATIONSecurity Agreement • November 14th, 2014 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _________________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five (5) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”), up to ___________________ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Common Stock [FORM OF] UNDERWRITING AGREEMENTUnderwriting Agreement • October 17th, 1997 • Cellegy Pharmaceuticals Inc • Pharmaceutical preparations • New York
AGREEMENTConsulting Agreement • March 28th, 1997 • Cellegy Pharmaceuticals Inc • Pharmaceutical preparations • California
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 21st, 2020 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of February 21, 2020, between Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
Exhibit 10.9 COMMON STOCK PURCHASE AGREEMENT by and between KINGSBRIDGE CAPITAL LIMITEDCommon Stock Purchase Agreement • April 6th, 2004 • Cellegy Pharmaceuticals Inc • Pharmaceutical preparations • New York
BASIC LEASE INFORMATION LEASE DATE: April 8, 1998 TENANT: CELLEGY PHARMACEUTICALS, INC. TENANT'S ADDRESS: Until the Term Commencement Date:Lease Agreement • May 8th, 1998 • Cellegy Pharmaceuticals Inc • Pharmaceutical preparations
Exhibit 4.4 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, PLEDGED, OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR...Warrant Agreement • November 7th, 2000 • Cellegy Pharmaceuticals Inc • Pharmaceutical preparations • California
PRE-FUNDED COMMON STOCK PURCHASE WARRANT ADAMIS PHARMACEUTICALS CORPORATIONPre-Funded Common Stock Purchase Warrant • July 13th, 2023 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Adamis Pharmaceuticals Corporation, a corporation incorporated under the laws of the state of Delaware (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
COMMON STOCK PURCHASE WARRANT ADAMIS PHARMACEUTICALS CORPORATIONCommon Stock Purchase Warrant • July 13th, 2023 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [_______] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after July ___, 2023 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on July ___, 2028 (the “Termination Date”), but not thereafter, to subscribe for and purchase from Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”), up to _______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder of this Warrant, subject to a
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 8th, 2013 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of April 5, 2013, between Adamis Pharmaceutical Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
Exhibit 10.6 May 15, 2003 K. Michael Forrest 18 Farm Lane Hillsborough, CA 94010 Re: Your Employment With Cellegy Pharmaceuticals, Inc. Dear Mike, This letter will set forth the binding agreement of employment (the "Agreement"), effective as of...Employment Agreement • April 6th, 2004 • Cellegy Pharmaceuticals Inc • Pharmaceutical preparations • California
COMMON STOCK PURCHASE WARRANT ADAMIS PHARMACEUTICALS CORPORATIONSecurities Agreement • July 12th, 2016 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _________, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Issue Date”) and on or prior to 11:59 P.M. on the five (5) year anniversary of the Issue Date or, if such day is not a Trading Day, on the next Trading Day (the “Termination Date”), but not thereafter, to subscribe for and purchase from Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”), up to __________ shares (as subject to adjustment hereunder, the “Warrant Shares”) of, at the election of the Holder, either (i) Common Stock, (ii) Series A-2 Convertible Preferred Stock, par value $0.0001 par value per share (“Preferred Stock”), or (iii) a combination of Common Stock and Preferred Stock. The purchase price of one share of Common Stock or Preferred Stock under this Warrant shall b
ADAMIS PHARMACEUTICALS CORPORATION and EQUINITI TRUST COMPANY, LLC, as Warrant Agent Warrant Agency Agreement Dated as of August 4, 2023 WARRANT AGENCY AGREEMENTWarrant Agency Agreement • November 14th, 2023 • DMK PHARMACEUTICALS Corp • Pharmaceutical preparations • New York
WARRANT AGENCY AGREEMENT, dated as of August 4, 2023 (“Agreement”), between Adamis Pharmaceuticals Corporation, a corporation organized under the laws of the State of Delaware (the “Company”), and Equiniti Trust Company, LLC (the “Warrant Agent”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 6th, 2022 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of July 5, 2022, between Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”), the purchaser identified on the signature pages hereto (including its successors and assigns, the “Purchaser”).
SECURITY AGREEMENTSecurity Agreement • January 15th, 2010 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations • New York
This SECURITY AGREEMENT, dated as of January 11, 2010 (this “Agreement”), is among Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”), each of the Subsidiaries of the Company other than Biosyn, Inc. and Cellegy Holdings, Inc. (such Subsidiaries, the “Guarantors”, and together with the Company, collectively the “Debtor” or “Debtors”), in favor of GEMINI STRATEGIES, LLC, as collateral agent (“Agent”) for all the holder(s) of the Company’s 10% Senior Secured Convertible Notes issued or to be issued in the original aggregate principal amount of up to $1,500,000 (the “Notes”) pursuant to the Purchase Agreement (as defined below) (collectively, together with their endorsees, transferees and assigns, the “Secured Parties”, and each individually, a “Secured Party”).
BETWEEN PDI, INC. ANDExclusive License Agreement • March 21st, 2003 • Cellegy Pharmaceuticals Inc • Pharmaceutical preparations • New York
ARTICLE I REGISTRATION RIGHTSRegistration Rights Agreement • April 6th, 2004 • Cellegy Pharmaceuticals Inc • Pharmaceutical preparations • New York
3,720,000 Shares Adamis Pharmaceuticals Corporation PURCHASE AGREEMENTPurchase Agreement • December 17th, 2013 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations • New York
Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 3,720,000 shares (the “Firm Shares”) of Common Stock, $0.0001 par value per share (the “Common Stock”), of the Company. The Company has also granted to the Underwriter an option to purchase up to 558,000 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement are herein collectively called the “Securities.”
Confidential AGREEMENTStock Purchase Agreement • November 7th, 2000 • Cellegy Pharmaceuticals Inc • Pharmaceutical preparations • New South Wales
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 16th, 2005 • Cellegy Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Registration Rights Agreement (the “Agreement”) is made and entered into as of this day of May, 2005, by and among Cellegy Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the “Investors” named in that certain Purchase Agreement by and among the Company and the Investors (the “Purchase Agreement”).
Adamis Pharmaceuticals Corporation Warrant To Purchase Common StockWarrant Agreement • November 12th, 2019 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations • New York
Adamis Pharmaceuticals Corporation, a company organized under the laws of Delaware (the "Company"), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged , [HOLDER], the registered holder hereof or its permitted assigns (the "Holder"), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined in Section 1(b) below) then in effect, at any time or times on or after the Issuance Date (the “Exercisability Date”), but not after 11:59 p.m., New York time, on the Expiration Date, (as defined in Section 16 below), ______________ (_____________) fully paid non-assessable shares of Common Stock (as defined in Section 16 below), subject to adjustment as provided herein (the "Warrant Shares"). Except as otherwise defined herein, capitalized terms in this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replaceme
PURCHASE AGREEMENTPurchase Agreement • July 12th, 2016 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations • New York
THIS PURCHASE AGREEMENT (“Agreement”) is made as of July 11, 2016, by and among Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”), and each entity named on the signature page of this Agreement (each an “Investor” and collectively, the “Investors”).
RECITALSServices Agreement • March 12th, 2002 • Cellegy Pharmaceuticals Inc • Pharmaceutical preparations • New York
40,540,540 Shares* Adamis Pharmaceuticals Corporation Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 29th, 2021 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations • New York
Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 40,540,540 shares of its Common Stock, par value $0.0001 per share (the “Common Stock”). The aggregate of 40,540,540 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 6,081,081 shares of Common Stock (the “Additional Shares”). The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 3rd, 2023 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of August 1, 2023, and is between Adamis Pharmaceuticals Corporation, a corporation incorporated under the laws of the state of Delaware (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 23rd, 2016 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations • California
THIS EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is dated as of December 31, 2015 (the “Effective Date”) and is entered into by and between Adamis Pharmaceuticals Corporation, a Delaware corporation (“Company”), and David J. Marguglio (“Executive”).
BETWEENExclusive Licensing Agreement • March 28th, 1997 • Cellegy Pharmaceuticals Inc • Pharmaceutical preparations • North Carolina
Intellectual Property: All patents, patent applications, registered and unregistered copyrights, registered and unregistered trademarks, trade names, service marks or service names, licenses or license agreements, clinical and pre-clinical data and...Binding Letter of Intent • November 6th, 1997 • Cellegy Pharmaceuticals Inc • Pharmaceutical preparations
SUBSCRIPTION AGREEMENTSubscription Agreement • July 2nd, 2013 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations • New York
THIS SUBSCRIPTION AGREEMENT (this “Agreement”), is dated as of June 26, 2013, by and between Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”), and the subscribers identified on Schedule 1 hereto, which may be amended from time to time prior to Closing (the “Subscribers”).
November 20, 1996 K. Michael Forrest 1065 E. Hillsdale Blvd. #418 Foster City, CA 94404 Re: Your Employment With Cellegy Pharmaceuticals, Inc. Dear Mike, This letter will set forth the binding agreement of employment ("the Agreement"), effective as of...Employment Agreement • March 28th, 1997 • Cellegy Pharmaceuticals Inc • Pharmaceutical preparations
